Find NOCITA at an Aratana booth during these upcoming conferences.
At VMX, formerly known as NAVC Conference, Aratana will host a half-day symposium showcasing NOCITA® (bupivacaine liposome injectable suspension), a long-acting local anesthetic that provides up to 72 hours of post-operative pain control following CCL surgery in dogs.
On Monday, February 5, Aratana will hold an educational CE session (8:00 -9:15 a.m.) featuring an interactive roundtable discussion with Kristin Kirkby-Shaw, DVM, MS, PhD, DACVS, DACVSMR, Mark Epstein, DVM, DABVP (Canine and Feline) and Tamara Grubb, DVM, PhD, DACVAA. The panel will detail how they have successfully incorporated NOCITA into their practice protocols and take questions from session attendees.
Aratana will also host a NOCITA lunch session for Veterinary Technicians (11:00 -12:30 p.m.) on Tuesday, February 6. Donna Sisak, CVT, LVT, VTS (Anesthesia) will present how NOCITA has helped her achieve a smooth and effective post-operative recovery.
Aratana will continue to showcase NOCITA® (bupivacaine liposome injectable suspension), a long-acting local anesthetic that provides up to 72 hours of pain control following CCL surgery in dogs, at the Western Veterinary Conference (WVC) in Las Vegas.
Aratana will hold another educational CE session (10:00 -10:50 p.m.) on Monday, March 5 with Duncan Lascelles, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DACVS, Kristin Kirkby-Shaw, DVM, MS, PhD, DACVS, DACVSMR and Mark Epstein, DVM, DABVP (Canine and Feline) participating in an interactive roundtable discussion on NOCITA, specifically detailing how they have successfully incorporated the long-acting local analgesic into their practice protocols.
Stop by the Aratana booth at Veterinary Orthopedic Society (VOS) in Snowmass Village on Saturday, March 10 through Saturday, March 17.
As a key sponsor, Aratana will feature NOCITA® (bupivacaine liposome injectable suspension), a long-acting local anesthetic that provides up to 72 hours of pain control following CCL surgery in dogs.
Learn more about NOCITA on your own schedule. View presentations by your peers regarding the latest methods in canine perioperative pain control.
*Continuing education accreditation provided for live-events only. Previously recording webinars are not RACE approved for CE.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
ENTYCE (capromorelin oral solution) provides appetite stimulation.
Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE provides safe, effective appetite stimulation.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
GALLIPRANT® (gapriprant tablets)
for the control of pain and inflammation associated with osteoarthritis in dogs.
GALLIPRANT is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.1
1Kirkby Shaw K, Rausch-Derra L, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2(1):3-9.
In co-promotion with Elanco
IMPORTANT SAFETY INFORMATION: Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If GALLIPRANT is used long term, appropriate monitoring is recommended. Concomitant use of GALLIPRANT with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of GALLIPRANT has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see the full Prescribing Information for more detail.